Recently diagnosed with HIV? Click here

Lersivirine

Lersivirine2.jpg

Lersivirine (UK-453061) is a second generation NNRTI (or non-nuke).

In Phase IA clinical trial designed to establish whether an experimental drug is safe for humans to take. Phase I studies determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and look for early evidence of effectiveness; these studies may include either people with HIV, HIV-negative volunteers, or both trials it proved to be effective against mutations of HIV which were resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. to first generation NNRTIs, like nevirapine and efavirenz. It is currently in Phase IIA smaller clinical trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase III study is undertaken, with a larger number of participaants, to confirm this. trials.

Generic name: Lersivirine (UK-453061)
Pronunciation:ler-SIV-arine
Drug class:non-nucleoside
Availability in Australia:
  • Not available on the Pharmaceutical Benefits Scheme (PBS).
  • This drug may be available through clinical trials in Australia.
Links:

Like most anti-HIV drugs, Lersivirine must be taken in combination with other drugs to be completely effective. Commonly, Lersivirine is combined with two nucleoside (NRTI) drugs, although other combinations are sometimes used. Your doctor will advise you on the right combination of drugs to suit your circumstances.

Side effects

All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.

  • Common side effects may include nausea (upset stomach, feeling sick to the stomach), headache.
  • Less common side effects may include rash, dizziness, abnormal dreams.

    • It's unlikely you will experience all of these side effects, and you may not experience any side effects at all. Before starting any new drug, ask your doctor about side effects you might experience and discuss strategies for dealing with side effects if they do occur. If you experience any significant side effect you should continue taking your medicine and see your doctor as soon as possible.

Interactions with other drugs

Sorry, no articles were found in this category.

The table below shows all the clinical trials in the database with the keyword UK-453,061.

Short titleStatus
Lersivirine long term safety study Not yet started
UK-453, 061 Concluded
Syndicate content
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Treatments database entry was first published on 1 June 2010 — more than one year ago.

While the content of this treatments database entry was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more